The 11 Biggest GLP-1 Myths, Busted by Expert Dietitians
If you’ve spent any time on social media lately, you might have seen conflicting claims about GLP-1 weight loss medications. One post says they’ll completely kill your appetite. Another warns about scary side effects. Someone else declares losing weight this way is “cheating.” With all the noise out there, it’s tough to know what’s actually […]
Inspire Medical (INSP) Fell Due to Multiple Headwinds
Mairs & Power, an investment advisor, released the third-quarter 2025 investor letter for the “Mairs & Power Small Cap Fund.” A copy of the letter can be downloaded here. The market’s concentration persists in 2025, with a few dominant mega-cap stocks tied to artificial intelligence (AI) driving most of the favorable outcomes. The fund returned […]
Here’s How GLP-1 Affected MGP Ingredients (MGPI) in Q3
Mairs & Power, an investment advisor, released the third-quarter 2025 investor letter for the “Mairs & Power Small Cap Fund.” A copy of the letter can be downloaded here. The market’s concentration persists in 2025, with a few dominant mega-cap stocks tied to artificial intelligence (AI) driving most of the favorable outcomes. The fund returned […]
STAT+: Pharmalittle: We’re reading about Lilly’s new obesity drug, E.U. pharma rules, and much more
Top of the morning to you, and a fine one it is. Although quite chilly so far, the clear, blue skies and warm sunshine are a heartening elixir for a busy day ahead. To cope, we are brewing fresh cups of stimulation. Our choice today is chocolate raspberry. As always you are invited to join […]
STAT+: Lilly’s next-gen obesity drug delivers major weight loss in Phase 3 trial, but with many discontinuations
Eli Lilly’s next-generation obesity drug led to what appears to be the most weight loss seen so far in a late-stage trial, but rates of side effects were high and many participants discontinued the treatment, including people who felt they were losing too much weight. In a 68-week Phase 3 study of patients with obesity […]
STAT+: Wave’s ‘gym bro’ obesity drug is story over substance
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I’m just back from the ASH meeting in Orlando, so a shorter-than-normal newsletter this week. “Mean Adam” is also back. You’ll see below. Continue to STAT+ to read the full story…
Fireside’s 2026 Vision: Mapping The Course Of Consumer Retail, D2C Ecosystem
With its fourth fund closed last week, Fireside Ventures is looking at a new landscape of consumer brands and retail in India. The INR 2,265 Cr (around $253 Mn) fund IV will look to invest in 30-35 consumer brands — a tried and tested thesis that has resulted in exits over the past few years. […]
Life, Vol. 15, Pages 1893: The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer’s and Parkinson’s Disease: A Literature Review of Clinical Trials
Life, Vol. 15, Pages 1893: The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer’s and Parkinson’s Disease: A Literature Review of Clinical Trials Life doi: 10.3390/life15121893 Authors: Joanna Pilśniak Julia Węgrzynek-Gallina Błażej Bednarczyk Aleksandra Buczek Aleksandra Pilśniak Tomasz Chmiela Agnieszka Jarosińska Joanna Siuda Michał Holecki Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the […]
Weight loss drugs for pets: Everything you need to know
Okava Pharmaceuticals, a biopharmaceutical company, has launched a pilot study of a GLP-1 drug for cats with obesity
Feel Like Everyone Is On GLP-1s? It’s About More Than Weight Loss
The GLP-1 craze isn’t going anywhere, but it is changing course.